News | July 01, 2022
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
Bringing next-gen cannabinoid therapeutics to cancer patients
Subscribe To Our Newsletter & Stay Updated
